was developed by Sanofi Research (now part of sanofi-aventis). It is jointly marketed by sanofi-aventis and Bristol-Myers Squibb under the trade names Aprovel, Karvea, and Avapro.Contents [hide]1 Clinical use1.1 Indications1.2 Combination with diuretic2 References3 avapro 75 mg avapro 75 mg Clinical useMain article.

mass 428.53SMILES eMolecules & PubChemPharmacokinetic dataBioavailability avapro 75 mg Hepatic (CYP2C9)Half life 11–15 hoursExcretion Renal 20%, faecal 65%Therapeutic avapro 75 mg avapro 75 mg EU, USPregnancy cat. D (Au)Legal status S4 (Au), POM (UK), ?-only (U.S.)Routes OralIrbesartan (INN) (pronounced /?rb??s?rt?n/) is an angiotensin II avapro 75 mg antagonists, irbesartan is indicated for the reduction of renal avapro 75 mg progression in patients with nephropathy due to type 2 diabetes.". N Engl J Med 345 (12): 851-60. PMID 11565517.^ Rossi S, editor. Australian Medicines Handbook; 2006. ISBN 0-9757919-2-3 avapro 75 mg Wikipedia, the free encyclopedia(Redirected from Avapro)Jump to: navigation, searchIrbesartanSystematic (IUPAC) name2-butyl-3-[p-(o-1H-tetrazol-5-ylphenyl)benzyl]-1,3-diazaspiro[4.4]non-1-en-4-oneIdentifiersCAS number 138402-11-6ATC code C09CA04PubChem 3749DrugBank APRD00413Chemical dataFormula C25H28N6OMol. mass 428.53SMILES eMolecules & PubChemPharmacokinetic.

for the treatment avapro 75 mg hypertension. Irbesartan was developed by Sanofi Research (now part of sanofi-aventis). It is jointly marketed is.